REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai > Cyclopeptides > Monocyclic MonocyclicMonocyclic patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/22/07 - 20070042943 - Novel cyclosporin galenic forms Pharmaceutical compositions comprising a cyclosporin as active ingredient, a fatty acid triglyceride, a glycerol fatty acid partial ester or propylene glycol or sorbitol complete or partial ester, preferably, and a tenside having an HLB of at least 10. ... 02/01/07 - 20070027072 - Pharmaceutical compositions comprising cyclosporins A composition is described herein comprising cyclosporin A, polysorbate 80, a polyoxyethylene stearate, and an oil; wherein the composition is an emulsion which is ophthalmically acceptable. Methods of treating diseases or conditions using said compositions, and medicaments related thereto, are also disclosed herein. ... 01/18/07 - 20070015694 - Cyclosporin compositions A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic adds/fatty acids, cellulose derivatives, ethoxylated alcohols, ... 01/18/07 - 20070015693 - Cyclosporin compositions Cyclosporin A compositions are disclosed herein comprising an oil and a surfactant. ... 01/18/07 - 20070015692 - Cyclosporin compositions A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein. ... 01/18/07 - 20070015691 - Cyclosporin compositions A composition is disclosed herein comprising from about 0.001% to about 0.4% cyclosporin A, castor oil, and a surfactant selected from the group consisting of alcohol ethoxylates, alcohols, alkyl glycosides, alkyl polyglycosides, alkylphenol ethoxylates, amine oxides, block polymers, carboxylated alcohol or alkylphenol ethoxylates, carboxylic acids/fatty acids, cellulose derivatives, ethoxylated alcohols, ... 01/18/07 - 20070015690 - Cyclosporin compositions A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein. ... 11/23/06 - 20060264359 - Blockade of pin1 prevents cytokine production by activated immune cells The invention provides pharmaceutical compositions and methods of treating immunological disorders. The invention also provides pharmaceutical compositions and methods of inducing eosinophil apoptosis, and methods for treating eosinophil-associated disorders comprising inducing eosinophil apoptosis in an individual in need thereof. ... 11/09/06 - 20060252675 - Use of selected cyclosporins for the treatment of hepatitis c infection This invention relates to the use in the treatment of HCV infection, either as single active agents or in combination with another active agent, of a cyclosporin having increased cyclophilin binding activity and essentially lacking immunosuppressive activity. ... 11/09/06 - 20060252674 - Methods for pretreating a subject with extracorporeal photopheresis The present invention relates to methods for treating a subject predisposed to an autoimmune disease with extracorporeal photopheresis or an effective amount of apoptotic cells before the clinical manifestation of a symptom associated with the autoimmune disease. The present invention alsorelates to methods for treating a subject predisposed to an ... 11/02/06 - 20060247159 - Therapeutic methods using cyclosporine components Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter pylori infection, duodenal ... 11/02/06 - 20060247158 - Therapeutic methods using cyclosporine components Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter pylori infection, duodenal ... 09/14/06 - 20060205639 - Pro-nanodispersion for the delivery of cyclosporin A novel cyclosporine formulation, which is a pro-nanodispersion at room temperature, featuring solid particles of a relatively large particle size (at least about 150 nm) and yet which is a nanodispersion at body temperature. ... 09/07/06 - 20060199760 - Methods for the therapeutic use of cyclosporine components Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter plylori infection, duodenal ... 08/17/06 - 20060183674 - Compositions and methods for treating diabetes Compositions and methods for islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided. ... 07/20/06 - 20060160727 - 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection wherein A, B, R1, R2 and X are as defined in the specification, and pharmaceutical compositions prepared from the same, for use in treatment of hepatitis C virus. ... 07/06/06 - 20060148686 - Ophthalmic compositions comprising steroid and cyclosporine for dry eye therapy The invention comprises a method of treating dry eye in a patient in need of such treatment. The treatment comprises administering to a patient in need thereof an ophthalmic pharmaceutical composition comprising a corticosteroid and cyclosporine. In a further embodiment of the invention the corticosteroid is loteprednol etabonate. In yet ... 06/22/06 - 20060135415 - Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier The present invention relates to the discovery that signaling via a serotonin type 1B, 2, 4 and 6 receptor is important in T cell activation such that inhibiting such signaling, such as by using fluphenazine, can be used to modulate the immune response, cell proliferation, and apoptosis, among other cell ... 06/22/06 - 20060135414 - Deuterated cyclosporine analogs and their use as immunomodulating agents Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution ... 05/18/06 - 20060105945 - Therapeutic methods using cyclosporine components Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter plylori infection, duodenal ... 05/18/06 - 20060105944 - Methods for the therapeutic use of cyclosporine components Methods of treating humans or animals having various conditions are disclosed which include administering a cyclosporine component. Among the conditions treated are dry mouth syndrome, verruciform xanthoma, achlorhydria, mucous cysts, oral submucous fibrosis, oral nevi, cancer of the oral mucosa, maloplakia of the genito-urinary tract, vulvovaginitis, helicobacter plylori infection, duodenal ... 05/04/06 - 20060094646 - Methods for inhibiting growth of prolactin-responsive cancer cells with cyclosporine a or other cyclophilin inhibitors Methods are provided for inhibiting growth of prolactin-responsive cancer cells and treating prolactin-responsive malignancies via administration an agent such as cyclosporine A which directly inhibits an enzymatic activity of a cyclophilin. ... 05/04/06 - 20060094645 - Method for defining and treating chemically-induced immune disorders using tumor necrosis factor (tfnalpha), interleukin-1 (ll-1), and interleulin-6r(ll-6r) antagonists Compositions and methods are disclosed for treating chemically-induced immune disorders. Pharmacological compositions comprising at least one TNF antagonist, at least one IL-1 antagonist, and at least one IL6R antagonist are disclosed. ... 04/27/06 - 20060089301 - 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection wherein A, B, R1, R2 and X are as defined in the specification, and pharmaceutical compositions prepared from the same, for use in treatment of hepatitis C virus. ... 04/06/06 - 20060074015 - Novel cyclosporin alkynes and their utility as pharmaceutical agents with X, R0, and R1 defined herein. ... 03/09/06 - 20060052290 - Deuterated cyclosporin analogs and their use as immunomodulating agents Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution ... 02/16/06 - 20060035822 - Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases Provided are novel cyclosporin analogs, methods for their production, and their use for treating immunoregulatory and respiratory diseases, disorders, and conditions. ... 02/16/06 - 20060035821 - Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases Provided are novel cyclosporin analogs, methods for their production, and their use for treating immunoregulatory and respiratory diseases, disorders, and conditions. ... 01/19/06 - 20060014677 - Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds The invention provides methods for predicting toxicity related to calcineurin inhibition therapy by measuring the peak concentration of drug and the trough concentration of the drug, calculating a peak-trough fluctuation, and comparing this peak-trough fluctuation to known values to predict if the patient will exhibit calcineurin-inhibition therapy-related toxicity. The invention ... 01/05/06 - 20060003927 - Modulation of immune function A method for modulating the immune system in a mammal is described comprising simultaneously, contemporaneously, separately or sequentially administering: i) an effective amount of an agonist of Notch signalling; and ii) an effective amount of an immunosuppressive agent. ... 12/29/05 - 20050288222 - Methods for enhancing the bioavailability of a drug The invention provides methods and compositions for enhancing the bioavailability of a drug in a subject. The present invention also provides methods and compositions for treating or preventing hepatic injury in a subject in need thereof. The invention further provides methods for identifying hydrophobic peptides, e.g., β-amyloid peptide derivatives, which ... 12/15/05 - 20050277585 - Combinations of immunosupressive agents for the treatment or prevention of graft rejections A pharmaceutical composition useful in the treatment or prevention of transgenic xenograft rejection comprising immunosuppressant compounds selected from the group consisting of an IL-2 transcription inhibitor and immunosuppressant compounds that immunosuppress for B-cell-mediated or antibody-mediated rejection of xenografts, and pharmaceutically acceptable diluents or carriers, and a method of preventing hyperacute ... 12/15/05 - 20050277584 - Pharmaceutical compositions comprising cyclosporins A liquid comprising a therapeutically effective concentration of a cyclosporin and a vitamin E tocopherol polyethylene glycol succinate, wherein said liquid is an aqueous solution, and wherein no hydrophilic organic solvent is present at a concentration greater than half of that of the cyclosporin is also disclosed herein. A composition ... 10/06/05 - 20050222016 - Nucleoside analogs in combination therapy of herpes simplex infections A pharmaceutical product comprising a nucleoside analogue active against herpes simplex virus, such as penciclorivir/famciclovir, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in the treatment and/or prevention of herpes simplex virus infections. ... 09/01/05 - 20050192214 - Cyclosporine analogue mixtures and their use as immunomodulating agents The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis ... 08/11/05 - 20050176628 - Deuterated cyclosporin analogs and their use as immunomodulating agents Cyclosporine derivatives are disclosed which possess enhanced efficacy and reduced toxicity over naturally occurring and other presently known cyclosporins and cyclosporine derivatives. The cyclosporine derivatives of the present invention are produced by chemical and isotopic substitution of the cyclosporine A (CsA) molecule by: (1) Chemical substitution and optionally deuterium substitution ... ### FreshPatents.com Support |